<DOC>
	<DOCNO>NCT02554903</DOCNO>
	<brief_summary>STUDY OBJECTIVES Primary objective ( ) To evaluate effect macitentan 10 mg pulmonary vascular resistance ( PVR ) compare placebo subject pulmonary hypertension ( PH ) leave ventricular assist device ( LVAD ) implantation . Secondary objective To evaluate effect macitentan 10 mg compare placebo cardio-pulmonary hemodynamics disease severity subject PH LVAD implantation . To evaluate safety tolerability macitentan 10 mg subject PH LVAD implantation . Exploratory objective To explore potential effect macitentan 10 mg compare placebo right ventricular function subject PH LVAD implantation . To explore potential effect macitentan 10 mg compare placebo select clinical event subject PH LVAD implantation . To explore potential effect macitentan 10 mg compare placebo renal function measure glomerular filtration rate ( GFR ) subject PH LVAD implantation .</brief_summary>
	<brief_title>Clinical Study Assess Efficacy Safety Macitentan Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>1 . Written inform consent prior initiation studymandated procedure . 2 . Males females ≥ 18 year age . 3 . Surgical implantation LVAD ( e.g. , HeartMate II HeartWare ) within 45 day prior Randomization . 4 . Hemodynamic evidence PH Baseline right heart catheterization ( RHC ) . Baseline RHC define last hemodynamic measurement LVAD implantation prior Screening . Baseline RHC obtain via either routine RHC pulmonary artery catheter . PH define : Mean pulmonary arterial pressure ( mPAP ) ≥ 25 mmHg Pulmonary artery wedge pressure ( PAWP ) ≤ 18 mmHg 5 . PVR &gt; 3 Wood unit . 6 . Stabilization patient removal pulmonary artery catheter , define : No LVAD pump speed/flow rate change 48 h prior Screening Stable dose diuretic 48 h prior Screening No intravenous ( i.v . ) inotropes vasopressor 48 hour ( h ) prior Screening Patient able ambulate 48 h prior Screening . 7 . A woman childbearing potential eligible : A negative serum pregnancy test Screening negative serum pregnancy test Baseline . Agreed undertake monthly serum pregnancy test study 30 day study drug discontinuation . Agreed use one method contraception / follow contraception scheme describe protocol Screening least 30 day study treatment discontinuation . 1 . Documented severe obstructive lung disease define : forced expiratory volume ( FEV ) 1 second / force vital capacity ( FEV1/FVC ) &lt; 0.7 associate FEV1 &lt; 50 % predict value bronchodilator administration . 2 . Documented moderate severe restrictive lung disease define : total lung capacity &lt; 60 % predict value . 3 . Documented pulmonary venoocclusive disease . 4 . Patients undergoing dialysis . 5 . Hemoglobin &lt; 8.5 g/dL Screening . 6 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 3 × upper limit normal ( ULN ) Screening . 7 . Severe hepatic impairment , e.g. , ChildPugh Class C liver disease . 8 . Body weight &lt; 40 kg Screening . 9 . Doppler mean blood pressure &lt; 65 mmHg Screening . 10 . GFR &lt; 30 mL/min Screening . 11 . Pregnant , plan become pregnant study period , breastfeed . 12 . Treatment endothelin receptor antagonist ( ERAs ) , phosphodiesterase5 ( PDE5 ) inhibitor , intravenous ( i.v ) . , subcutaneous ( s.c. ) , oral prostanoids , guanylate cyclase stimulators within 7 day prior Baseline RHC , plan treatment study period . 13 . Treatment inhaled prostanoids ( e.g. , iloprost , epoprostenol ) nitric oxide within 24 h prior Baseline RHC , plan treatment study period . 14 . Treatment i.v . inotropes vasopressor within 24 h prior Baseline RHC . 15 . Treatment strong inducer cytochrome P450 isozyme 3A4 ( CYP3A4 ) within 28 day prior study treatment initiation ( e.g. , carbamazepine , rifampicin , rifabutin , phenytoin St. John 's Wort ) . 16 . Treatment strong inhibitor CYP3A4 within 28 day prior study treatment initiation ( e.g. , ketoconazole , itraconazole , voriconazole , clarithromycin , telithromycin , nefazodone , ritonavir , saquinavir , boceprevir , telaprevir , iopinavir , fosamprenavir , darunavir , tipranavir , atazanavir , nelfinavir , amprenavir , idinavir ) . 17 . Treatment another investigational drug ( plan , take within 28 day prior Baseline RHC ) . 18 . Known hypersensitivity ERAs , study treatment excipients . 19 . Any condition prevents compliance protocol adherence therapy . 20 . Known concomitant lifethreatening disease life expectancy &lt; 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>LVAD</keyword>
</DOC>